Oncodesign Precision Medicine, a biopharmaceutical company specializing in medicine for the treatment of resistant and metastatic cancers, announced that it will launch an IPO on Euronext Access + Paris through a direct quotation Oct. 5.
The company intends to offer nearly 6.9 million shares at €0.817 each (approximately $5.9 million). Read more.
